ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?

Journal of Neuroscience Methods

Volumn 214, Issue 1, 2013, Pages 62-68

  Gillardon, Frank ^a   Kremmer, Elisabeth ^b   Froehlich, Thomas ^d   Ueffing, Marius ^b,c   Hengerer, Bastian ^a   Gloeckner, Christian J ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Activation segment; Antibody; Conformation; Immunoprecipitation; Kinase domain; LRRK2

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DRUG BINDING; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN REFOLDING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; BENZODIAZEPINONES; BINDING, COMPETITIVE; ENZYME ACTIVATION; EPITOPES; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; RECOMBINANT PROTEINS; SWISS 3T3 CELLS;

EID: 84873431777     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2012.12.015     Document Type: Article

References (24)

1. Abeliovich A., Flint B.M. Parkinsonism genes: culprits and clues. J Neurochem 2006, 99:1062-1072.
2. Biskup S., West A.B. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 2009, 1792:625-633.
3. Deng X., Dzamko N., Prescott A., Davies P., Liu Q., Yang Q., et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 2011, 7:203-205.
4. Dzamko N., Deak M., Hentati F., Reith A.D., Prescott A.R., Alessi D.R., et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 2010, 430:405-413.
5. Dzamko N., Inesta-Vaquera F., Zhang J., Xie C., Cai H., Arthur S., et al. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 2012, 7:e39132.
6. Frank R., Overwin H. SPOT synthesis. Epitope analysis with arrays of synthetic peptides prepared on cellulose membranes. Methods Mol Biol 1996, 66:149-169.
7. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in parkinsonian neurodegeneration?. J Neurochem 2009, 110:1514-1522.
8. Gloeckner C.J., Boldt K., Schumacher A., Roepman R., Ueffing M. A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 2007, 7:4228-4234.
9. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006, 15:223-232.
10. Greggio E., Zambrano I., Kaganovich A., Beilina A., Taymans J.M., Daniels V., et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 2008, 283:16906-16914.
11. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002, 109:275-282.
12. Ito G., Iwatsubo T. Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem J 2012, 441:987-994.
13. Kamikawaji S., Ito G., Iwatsubo T. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009, 48:10963-10975.
14. Kumar A., Greggio E., Beilina A., Kaganovich A., Chan D., Taymans J.M., et al. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 2010, 5:e8730.
15. Li X., Moore D.J., Xiong Y., Dawson T.M., Dawson V.L. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem 2010, 285:29569-29576.
16. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 2006, 29:286-293.
17. Melrose H. Update on the functional biology of LRRK2. Future Neurol 2008, 3:669-681.
18. Nichols R.J., Dzamko N., Hutti J.E., Cantley L.C., Deak M., Moran J., et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 2009, 424:47-60.
19. Nichols R.J., Dzamko N., Morrice N.A., Campbell D.G., Deak M., Ordureau A., et al. 14-3-3 Binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 2010, 430:393-404.
20. Nolen B., Taylor S., Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 2004, 15:661-675.
21. Pandey N., Fahey M.T., Jong Y.J., O'Malley K.L. Sequences located within the n-terminus of the PD-Linked LRRK2 lead to increased aggregation and attenuation of 6-hydroxydopamine-induced cell death. PLoS One 2012, 7:e45149.
22. Sen S., Webber P.J., West A.B. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem 2009, 284:36346-36356.
23. Taymans J.M., Cookson M.R. Mechanisms in dominant Parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 2010, 32:227-235.
24. Wang L., Xie C., Greggio E., Parisiadou L., Shim H., Sun L., et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 2008, 28:3384-3391.